Results from the combined analysis of two European Phase II trials have been presented at the 3rd European Lung Cancer Conference in Geneva, Switzerland. Biodesix' VeriStrat retrospective analysis was performed on serum samples from advanced non-squamous non-small cell lung cancer (NSCLC) patients treated with the combination therapy of Genentech's (Roche) Avastin (bevacizumab) and OSI Pharmaceuticals' (Astellas Pharma) Tarceva (erlotinib). Results showed that the VeriStrat test was able to identify patients likely to have better and worse survival outcomes when treated with the combination therapy.
Pretreatment serum samples from 114 patients treated with bevacizumab+erlotinib were classified as either VeriStrat Good or VeriStrat Poor. The study showed there was a statistically significant difference in overall survival between the two groups. Patients classified as VeriStrat Good had a median overall survival of 13.4 months versus 6.2 months for patients classified as VeriStrat Poor (p=0.0027, HR=0.480, 95 per cent CI:0.294-0.784). Median progression free survival for patients classified as VeriStrat Good was 4 months and 3.2 months for patients classified as VeriStrat Poor, but this difference was not statistically significant (p=0.2632, HR=0.768, 95 per cent CI: 0.482-1.223).
Researchers concluded that the VeriStrat test may be useful for clinical decision-making, representing a prognostic and potentially predictive biomarker for treatment with erlotinib and erlotinib combinations. Prospective trials are ongoing, including a Phase III trial in advanced squamous cell lung cancer, sponsored by the European Thoracic Oncology Platform.
VeriStrat is a serum proteomic test currently available for patients with advanced NSCLC. The test identifies patients who are likely to have good or poor outcomes after treatment with epidermal growth factor receptor inhibitors. Samples are processed in Biodesix' CLIA-certified laboratory and results are typically reported within 72 hours of sample shipment.